Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D…
Lucid Diligence Brief: Pinnacle Medicines $89 million Series B
Lucid Diligence Brief: Pinnacle Medicines $89 million Series B Professional…
Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery…
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines Professional…
Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal
Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal Professional…
Lucid Diligence Brief: Teva and Blackstone Life Sciences $400m duvakitug financing
Lucid Diligence Brief: Teva and Blackstone Life Sciences $400m duvakitug…
Lucid Diligence Brief: Poplar Therapeutics $95 million Series A
Lucid Diligence Brief: Poplar Therapeutics $95 million Series A extension…
Lucid Diligence Brief: OSE Immunotherapeutics refocus on lusvertikimab and Tedopi
Lucid Diligence Brief: OSE Immunotherapeutics refocus on lusvertikimab and…
Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”
Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”…
AAAAI 2026 Preview: Key Allergy, Asthma and Immunology Highlights to Watch
AAAAI 2026 at a Glance Get ready for AAAAI 2026. LucidQuest’s preview brings…
Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal
Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics…
Lucid Diligence Brief: Turbine $25m Series B for virtual biology
Lucid Diligence Brief: Turbine $25m Series B for virtual biology Professional…